Zydus acquires derma brand Melgain from Issar Pharma
The brand will be marketed by Liva Healthcare, the group's division catering to dermatological segment08-08-2016
08-08-2016
Outcome of AGM
Zydus Wellness Ltd has submitted to BSE a copy of the proceedings of the 22nd Annual General Meeting (AGM) of the Company held on August 03, 2016.03-08-2016
Results of E-Voting and Poll of AGM
Zydus Wellness Ltd has informed BSE regarding announcement of the consolidated Results of E-Voting and Poll conducted at the Twenty Second Annual General Meeting of the Company held on August 03, 2016.03-08-2016
Zydus Wellness Q1 profit up 20.12% at Rs23.46 crore
Consolidated total income of Zydus Wellness rises to `108.78 crore in June quarter as against `96.82 crore in the year ago period02-08-2016
Standalone & Consolidated Financial Results, Limited Review Report, Results Press Release for June 30, 2016
Zydus Wellness Ltd has informed BSE about : 1. Standalone Financial Results for the period ended June 30, 20162. Consolidated Financial Results for the period ended June 30, 20163. Standalone Limited Review for the period ended June 30, 20164. Consolidated Limited Review for the period ended June 30, 20165. Result Press Release for the period ended June 30, 201602-08-2016
Schedule of Analyst/Institutional Investors' meet
Zydus Wellness Ltd has informed BSE that the Company has planned investor interaction through a conference call on August 02, 2016 at 4:00 p.m. post announcement of unaudited financial results for the quarter ended on June 30, 2016.The details of the conference call is uploaded on the website of the Company.22-07-2016
AGM on August 03, 2016
Zydus Wellness Ltd has informed BSE that the 22nd Annual General Meeting (AGM) of the Company will be held on August 03, 2016.11-07-2016
Board Meeting Intimation for Results & Closure of Trading Window
Zydus Wellness Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on August 02, 2016, inter alia, to consider & approve the unaudited financial results for the quarter ended on June 30, 2016.Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will remain closed from July 24, 2016 to...11-07-2016
Zydus gets FDA nod for diabetes drug
The company today informed in a statement that it has received the nod from the US drug regulator to market the drug in strengths of 60 mg and 120 mg11-07-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
Zydus Wellness Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.07-07-2016